Pharmaceutical Safety Assessment Market Report 2026

The pharmaceutical safety assessment market size has grown strongly in recent years. It will grow from $11.32 billion in 2025 to $12.24 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to expansion of pharmaceutical R&D pipelines, increasing regulatory scrutiny on drug safety, growth in preclinical and clinical testing volumes, wider adoption of in-vitro safety assessment methods, rising use of CRO-led safety studies.

The pharmaceutical safety assessment market size is expected to see strong growth in the next few years. It will grow to $16.97 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing reliance on computational safety assessment, expansion of personalized medicine development, rising demand for faster regulatory approvals, growing integration of ai in drug safety workflows, increased post-market surveillance requirements. Major trends in the forecast period include increasing use of ai-based toxicity prediction tools, rising adoption of in-silico safety assessment models, growing integration of real-time pharmacovigilance systems, expansion of automated preclinical testing platforms, enhanced focus on regulatory-compliant safety analytics.

The expansion of clinical trials is anticipated to drive the growth of the pharmaceutical safety assessment market in the coming years. Clinical trials are research studies conducted in humans to assess the safety, efficacy, and potential side effects of new medical treatments, drugs, or interventions. The number of clinical trials is increasing due to the rising demand for novel and effective therapies, as researchers and healthcare providers strive to develop treatments that can better prevent, manage, or cure diseases. Clinical trials contribute to pharmaceutical safety assessment by systematically examining a drug’s impact on humans through carefully controlled studies, monitoring for adverse effects, determining safe dosage ranges, and providing critical data that regulatory authorities use to ensure medications are both safe and effective for public use. For example, as of September 26, 2025, the National Library of Medicine (NLM), a US-based biomedical library, reported that a total of 554,798 studies were registered on ClinicalTrials.gov. Thus, the growth of clinical trials is supporting the expansion of the pharmaceutical safety assessment market.

Major companies in the pharmaceutical safety assessment market are concentrating on developing AI-powered decision support tools to improve the accuracy and efficiency of toxicity prediction and safety profiling. An AI-powered decision support tool is a software system that employs artificial intelligence to analyze data and provide insights that facilitate faster and more precise decision-making. For example, in April 2024, Charles River Laboratories, a US-based life sciences company, in collaboration with Deciphex, an Ireland-based company specializing in AI-driven quality assurance, launched the Patholytix Foresight platform, an AI-powered decision support tool aimed at transforming toxicologic pathology in pharmaceutical safety assessment. The platform utilizes artificial intelligence to rapidly analyze complex preclinical pathology data, assisting in the earlier identification of potential safety risks and minimizing subjectivity in results. It provides distinctive features such as an AI algorithm for detecting tissue abnormalities, a cloud-based system for global collaboration, and a scalable design that reduces slide review time while enhancing data accuracy and consistency.

In January 2025, Groupe ProductLife S.A.S., a France-based life sciences services company, acquired Stragen Services SAS for an undisclosed amount. Through this acquisition, ProductLife Group intends to strengthen its pharmacovigilance and clinical safety capabilities, broaden its presence in the European market, and offer more comprehensive regulatory and safety support to pharmaceutical and biotech clients. Stragen Services SAS is a France-based company that focuses on pharmaceutical safety assessment, also known as pharmacovigilance.

Major companies operating in the pharmaceutical safety assessment market are IQVIA Holding Inc., LabCorp (formerly Covance), Thermo Fisher Scientific (PPD), Charles River Laboratories, ICON plc, Parexel International Corp., Syneos Health, Eurofins Scientific SE, Wuxi Biologics Inc., SGS SA, Medpace Holdings Inc., Fujifilm Wako (Fujifilm Corp.), Pharmaron Beijing Co. Ltd., Inotiv (incl. Envigo), Evotec (Cyprotex), Intertek Group, Altasciences Inc., Aragen Life Sciences Ltd., CTI Clinical Trial and Consulting Inc., ChemDiv Inc., Frontage Laboratories, Medicilon Inc., Biotoxtech Co. Ltd., BioIVT, Accelera Srl.

North America was the largest region in the pharmaceutical safety assessment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical safety assessment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical safety assessment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the pharmaceutical safety assessment market by increasing costs of imported laboratory instruments, analytical software platforms, high-throughput screening systems, and specialized testing equipment used across in-vitro, in-vivo, and computational assessments. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported analytical technologies, while Asia-Pacific faces cost pressure on outsourced safety testing services. These tariffs are increasing operational costs and extending assessment timelines. However, they are also encouraging domestic development of safety assessment tools, regional CRO expansion, and increased adoption of software-based and in-silico safety solutions.

The pharmaceutical safety assessment market research report is one of a series of new reports that provides pharmaceutical safety assessment market statistics, including pharmaceutical safety assessment industry global market size, regional shares, competitors with a pharmaceutical safety assessment market share, detailed pharmaceutical safety assessment market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical safety assessment industry. This pharmaceutical safety assessment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical safety assessment involves the systematic evaluation of drugs and pharmaceutical products to confirm their safety and reduce potential risks to patients. It includes the analysis of preclinical and clinical data, monitoring of adverse effects, and adherence to regulatory standards. This process supports informed decision-making regarding the approval, labeling, and safe use of medications.

The main types in the pharmaceutical safety assessment market include in-vitro safety assessment, in-vivo safety assessment, and computational safety assessment. In-vitro safety assessment involves evaluating the safety and toxicity of drugs, chemicals, or other substances through controlled laboratory tests conducted outside a living organism. The different types of drugs comprise biological drugs and chemical drugs. It covers multiple stages, such as preclinical, clinical (phase I, II, III), and post-market surveillance (phase IV). Major end users consist of pharmaceutical companies, biotechnology firms, medical device manufacturers, academic and research institutions, and contract research organizations (CROs).

The pharmaceutical safety assessment market includes revenues earned by entities by providing services such as post-marketing surveillance, safety pharmacology, regulatory consulting and compliance, bioanalytics and biomarker services, and in silico and computational toxicology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.